Status:

COMPLETED

The Effects of Aripiprazole on Patients With Metabolic Syndrome

Lead Sponsor:

New Mexico VA Healthcare System

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

Schizophrenia

Schizoaffective Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.

Detailed Description

Schizophrenia, schizoaffective disorder and bipolar disorder are severe and disabling disorders, associated with marked social or occupational dysfunction, tenfold suicidal risk, intensive healthcare ...

Eligibility Criteria

Inclusion

  • Males or females with DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder who, based on chart review, have developed significant weight gain or any clinically significant aspect of the metabolic syndrome including weight gain, hyperglycemia, diabetes, or hyperlipidemia, while on a second generation antipsychotic medication.
  • Between 18-65 years of age
  • Decisional capacity is adequate to provide informed consent or has an authorized appropriate surrogate decision maker.
  • If female, must agree to use a medically approved contraceptive or does not possess potential to bear children

Exclusion

  • History of adverse reaction to aripiprazole
  • Serious hepatic, renal, cardiac, neurological, or pulmonary disease that would prevent safe participation in a drug trial
  • A diagnosis of active drug or alcohol abuse according to DSM-IV criteria within the last 30 days
  • Suicidal or homicidal ideation or psychotic decompensation
  • Patients on Paxil, Remeron, tricyclic or monoamine oxidase inhibitor (MAOI) antidepressants or mood stabilizers other than lamotrigine.

Key Trial Info

Start Date :

March 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT00224822

Start Date

March 1 2004

End Date

March 1 2007

Last Update

March 24 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New Mexico VA Healthcare System

Albuquerque, New Mexico, United States, 87108

The Effects of Aripiprazole on Patients With Metabolic Syndrome | DecenTrialz